Li, Yingxin http://orcid.org/0000-0001-8079-7555
Li, Yang
Li, Li
Xue, Wei
Xin, Kong
Wang, Titi
Shi, Aixin
Funding for this research was provided by:
Sanofi
Article History
Accepted: 8 May 2023
First Online: 3 June 2023
Declarations
:
: This study was funded by Sanofi.
: Yingxin Li, Li Li, and Kong Xin are employees of Sanofi and may hold shares and/or stock options (< 5%) in the company. Yang Li, Wei Xue, Titi Wang, and Aixin Shi have no conflicts of interest.
: The original data used for analysis in the current study will not be openly shared due to confidentiality concerns.
: Not applicable.
: YL, LL, and AS were responsible for study concept and study design. YL, YL, LL, WX, TW, and AS were responsible for study conduct and data acquisition. YL, LL, and AS were responsible for analysis and interpretation. YL, YL, LL, WX, KX, TW, and AS were responsible for the manuscript (draft, review, and approval). The authors, individually and collectively, are responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication.
: The study was approved with an approval number of 2020BJYYEC-176-02 by the Ethics Committee of Beijing Hospital. The study was undertaken in accordance with the consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki, and the International Council of Harmonization guidelines for Good Clinical Practice. All volunteers gave their written informed consent prior to any study-related procedure.
: All volunteers gave their written informed consent prior to any study-related procedure.
: Not applicable.